Deciphering PI3K biology in health and disease

Project Information

Phd

Grant agreement ID: 675392

DOI 10.3030/675392

Project closed

EC signature date 7 August 2015

Start date 1 November 2015

End date 31 October 2019

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost € 3 896 148,12

EU contribution € 3 896 148,12

Coordinated by

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Spain

Deliverables

Other (6)

Research Training Workshop 2

Research Training Workshop

Research Training Workshop 3

Research Training Workshop

Recruitment
Research Training Workshop 4

Research Training Workshop

PhD Completion

Phd Completion

Research Training Workshop 1

Research Training Workshop

Documents, reports (5)

Dissemination and Outreach Plan 1

Dissemination and Outreach Plan

Dissemination and Outreach Plan 2

Dissemination and Outreach Plan

Dissemination and Outreach Plan 3

Dissemination and Outreach Plan

Mid-term review meeting

Meeting with fellows, members of consortium and REA representative to assess the work progress and achievements

Dissemination and Outreach Plan 4

Dissemination and Outreach Plan

Websites, patent fillings, videos etc. (2)

Network Website
Promotional Video

Publications

Peer reviewed articles (5)

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility

Author(s): Ana Angulo-Urarte, Pedro Casado, Sandra D. Castillo, Piotr Kobialka, Maria Paraskevi Kotini, Ana M. Figueiredo, Pau Castel, Vinothini Rajeeve, Maria Milà-Guasch, Jaime Millan, Cora Wiesner, Helena Serra, Laia Muixi, Oriol Casanovas, Francesc Viñals, Markus Affolter, Holger Gerhardt, Stephan Huveneers, Heinz-Georg Belting, Pedro R. Cutillas, Mariona Graupera
Published in: Nature Communications, Issue 9/1, 2018, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-018-07172-3

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Author(s): Florent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, Thomas Bohnacker, Anna Melone, Romina Marone, Eileen Jackson, Xuxiao Zhang, Alexander Sele, Chiara Borsari, Jürgen Mestan, Paul Hebeisen, Petra Hillmann, Bernd Giese, Marketa Zvelebil, Doriano Fabbro, Roger L. Williams, Denise Rageot, Matthias P. Wymann
Published in: Journal of Medicinal Chemistry, Issue 60/17, 2017, Page(s) 7524-7538, ISSN 0022-2623
Publisher: American Chemical Society
DOI: 10.1021/acs.jmedchem.7b00930

The role of metabolic adaptation to nutrient stress in pancreatic cancer

Author(s): Abhishek Derle, Maria Chiara De Santis, Luca Gozzelino, Edoardo Ratto, Miriam Martini
Published in: Cell Stress, Issue 2/12, 2018, Page(s) 332-339, ISSN 2523-0204
Publisher: Shared Science Publishers
DOI: 10.15698/cst2018.12.166

Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics

Author(s): Célia Cintas, Thibaut Douché, Nicole Therville, Silvia Arcucci, Fernanda Ramos-Delgado, Céline Basset, Benoît Thibault, Julie Guillermet-Guibert
Published in: Cancers, Issue 10/6, 2018, Page(s) 174, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers10060174

Experimental pancreatic cancer develops in soft pancreas: novel leads for an individualized diagnosis by ultrafast elasticity imaging

Author(s): Nicole Therville, Silvia Arcucci, Aurélie Vertut, Fernanda Ramos-Delgado, Dina Ferreira Da Mota, Marlène Dufresne, Céline Basset, Julie Guillermet-Guibert
Published in: Theranostics, Issue 9/22, 2019, Page(s) 6369-6379, ISSN 1838-7640
Publisher: Ivyspring International Publisher
DOI: 10.7150/thno.34066